BACKGROUND: Tropomyosin (TM), an essential actin-binding protein, is central to the control of calcium-regulated striated muscle contraction. Although TPM1alpha (also called alpha-TM) is the predominant TM isoform in human hearts, the precise TM isoform composition remains unclear. METHODS AND RESULTS: In this study, we quantified for the first time the levels of striated muscle TM isoforms in human heart, including a novel isoform called TPM1kappa. By developing a TPM1kappa-specific antibody, we found that the TPM1kappa protein is expressed and incorporated into organized myofibrils in hearts and that its level is increased in human dilated cardiomyopathy and heart failure. To investigate the role of TPM1kappa in sarcomeric function, we generated transgenic mice overexpressing cardiac-specific TPM1kappa. Incorporation of increased levels of TPM1kappa protein in myofilaments leads to dilated cardiomyopathy. Physiological alterations include decreased fractional shortening, systolic and diastolic dysfunction, and decreased myofilament calcium sensitivity with no change in maximum developed tension. Additional biophysical studies demonstrate less structural stability and weaker actin-binding affinity of TPM1kappa compared with TPM1alpha. CONCLUSIONS: This functional analysis of TPM1kappa provides a possible mechanism for the consequences of the TM isoform switch observed in dilated cardiomyopathy and heart failure patients.
BACKGROUND: Tropomyosin (TM), an essential actin-binding protein, is central to the control of calcium-regulated striated muscle contraction. Although TPM1alpha (also called alpha-TM) is the predominant TM isoform in human hearts, the precise TM isoform composition remains unclear. METHODS AND RESULTS: In this study, we quantified for the first time the levels of striated muscle TM isoforms in human heart, including a novel isoform called TPM1kappa. By developing a TPM1kappa-specific antibody, we found that the TPM1kappa protein is expressed and incorporated into organized myofibrils in hearts and that its level is increased in humandilated cardiomyopathy and heart failure. To investigate the role of TPM1kappa in sarcomeric function, we generated transgenic mice overexpressing cardiac-specific TPM1kappa. Incorporation of increased levels of TPM1kappa protein in myofilaments leads to dilated cardiomyopathy. Physiological alterations include decreased fractional shortening, systolic and diastolic dysfunction, and decreased myofilament calcium sensitivity with no change in maximum developed tension. Additional biophysical studies demonstrate less structural stability and weaker actin-binding affinity of TPM1kappa compared with TPM1alpha. CONCLUSIONS: This functional analysis of TPM1kappa provides a possible mechanism for the consequences of the TM isoform switch observed in dilated cardiomyopathy and heart failurepatients.
Authors: J H Brown; K H Kim; G Jun; N J Greenfield; R Dominguez; N Volkmann; S E Hitchcock-DeGregori; C Cohen Journal: Proc Natl Acad Sci U S A Date: 2001-07-03 Impact factor: 11.205
Authors: Ganapathy Jagatheesan; Sudarsan Rajan; Natalia Petrashevskaya; Arnold Schwartz; Greg Boivin; Susan Vahebi; Pieter DeTombe; R John Solaro; Erin Labitzke; George Hilliard; David F Wieczorek Journal: J Biol Chem Date: 2003-04-10 Impact factor: 5.157
Authors: Kathy Pieples; Grace Arteaga; R John Solaro; Ingrid Grupp; John N Lorenz; Greg P Boivin; Ganapathy Jagatheesan; Erin Labitzke; Pieter P DeTombe; John P Konhilas; Thomas C Irving; David F Wieczorek Journal: Am J Physiol Heart Circ Physiol Date: 2002-06-13 Impact factor: 4.733
Authors: R Prabhakar; G P Boivin; I L Grupp; B Hoit; G Arteaga; R J Solaro; D F Wieczorek Journal: J Mol Cell Cardiol Date: 2001-10 Impact factor: 5.000
Authors: J van der Velden; Z Papp; R Zaremba; N M Boontje; J W de Jong; V J Owen; P B J Burton; P Goldmann; K Jaquet; G J M Stienen Journal: Cardiovasc Res Date: 2003-01 Impact factor: 10.787
Authors: Sudarsan Rajan; Ganapathy Jagatheesan; Natalia Petrashevskaya; Brandon J Biesiadecki; Chad M Warren; Tara Riddle; Stephen Liggett; Beata M Wolska; R John Solaro; David F Wieczorek Journal: J Biol Chem Date: 2018-12-19 Impact factor: 5.157
Authors: Chehade N Karam; Chad M Warren; Sudarsan Rajan; Pieter P de Tombe; David F Wieczorek; R John Solaro Journal: J Muscle Res Cell Motil Date: 2011-01-09 Impact factor: 2.698
Authors: Tara N Rindler; Valerie M Lasko; Michelle L Nieman; Motoi Okada; John N Lorenz; Jerry B Lingrel Journal: Am J Physiol Heart Circ Physiol Date: 2013-02-22 Impact factor: 4.733
Authors: Syamalima Dube; Lynn Abbott; Samender Randhawa; Yingli Fan; Joseph W Sanger; Jean M Sanger; Bernard J Poiesz; Dipak K Dube Journal: Int J Biochem Mol Biol Date: 2021-02-15